gastric cancer
Conditions
Interventions
None listed
Sponsors
Department of Clinical Pharmacology and Genitics, School of Pharmaceutical Science, Univercity of Shizuoka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically confirmed Gastric cancer 2) Life expectancy of at least 12 weeks at the pre-treatment evaluation 3) No prior chemotherapy or radiotherapy before enrollment 4) Oral intake is possible 5) 20 years of age or older 6) ECOG PS 0-2 7) Adequate organ function obtained within 2 weeks prior to registration. Laboratory values must be as follows; WBC count >= 3,000 /mm3, and <= 12,000 /mm3 absolute neutrophil count >= 1,500 /mm3, hemoglobin >= 8.0 g/dL platelet count >= 100,000 /mm3 AST <= 100 IU/L ALT <= 100 IU/L total bilirubin less than or equal to 1.5 mg/dL serum creatinine <= 1.5 mg/dL 8)Informed consent by the document
Exclusion criteria
Exclusion criteria: 1) Known prior severe hypersensitivity to clinical trial medicines 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Pregnant, breastfeeding or expecting woman 4) Other clinical difficulties in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the single nucleotide polymorphisms correlated with S-1 induced adverse drug reactions | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To investigate the single nucleotide polymorphisms correlated with progression-free survival (advanced gastric cancer) 2) To investigate the single nucleotide polymorphisms correlated with recurrence-free survival (resectable gastric cancer) | — |
Countries
Japan
Contacts
Public ContactDaiki Tsuji
Univercity of Shizuoka School of Pharmaceutical Science
Outcome results
None listed